Trends in net survival from pancreatic cancer in six European Latin countries: Results from the SUDCAN population-based study

A.-M. Bouvier, N. Bossard, M. Colonna, A. Garcia-Velasco, M. Carulla, S. Manfredi, Diego Serraino, Antonella Zucchetto

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10%). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)S63-S69
Number of pages7
JournalEuropean Journal of Cancer Prevention
Volume26
Issue numbersupp 1
DOIs
Publication statusPublished - 2017

Fingerprint

Pancreatic Neoplasms
Survival
Population
Portugal
Mortality
Belgium
Switzerland
Spain
Italy
France
Demography
Databases
Health

Keywords

  • Cancer registries
  • Europe
  • Excess mortality rate
  • Net survival
  • Pancreatic cancer
  • Trend analysis
  • adolescent
  • adult
  • aged
  • Article
  • Belgium
  • cancer epidemiology
  • cancer prognosis
  • cancer registry
  • female
  • France
  • human
  • Italy
  • major clinical study
  • male
  • mortality rate
  • pancreas cancer
  • Portugal
  • priority journal
  • Spain
  • survival
  • Switzerland
  • trend study

Cite this

Trends in net survival from pancreatic cancer in six European Latin countries: Results from the SUDCAN population-based study. / Bouvier, A.-M.; Bossard, N.; Colonna, M.; Garcia-Velasco, A.; Carulla, M.; Manfredi, S.; Serraino, Diego; Zucchetto, Antonella.

In: European Journal of Cancer Prevention, Vol. 26, No. supp 1, 2017, p. S63-S69.

Research output: Contribution to journalArticle

Bouvier, A.-M. ; Bossard, N. ; Colonna, M. ; Garcia-Velasco, A. ; Carulla, M. ; Manfredi, S. ; Serraino, Diego ; Zucchetto, Antonella. / Trends in net survival from pancreatic cancer in six European Latin countries: Results from the SUDCAN population-based study. In: European Journal of Cancer Prevention. 2017 ; Vol. 26, No. supp 1. pp. S63-S69.
@article{59edfce04d054debb20e2dc2d91d4267,
title = "Trends in net survival from pancreatic cancer in six European Latin countries: Results from the SUDCAN population-based study",
abstract = "Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10{\%}). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis. Copyright {\circledC} 2017 Wolters Kluwer Health, Inc. All rights reserved.",
keywords = "Cancer registries, Europe, Excess mortality rate, Net survival, Pancreatic cancer, Trend analysis, adolescent, adult, aged, Article, Belgium, cancer epidemiology, cancer prognosis, cancer registry, female, France, human, Italy, major clinical study, male, mortality rate, pancreas cancer, Portugal, priority journal, Spain, survival, Switzerland, trend study",
author = "A.-M. Bouvier and N. Bossard and M. Colonna and A. Garcia-Velasco and M. Carulla and S. Manfredi and Diego Serraino and Antonella Zucchetto",
note = "Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Bouvier, A.-M.; Registre Bourguignon des Cancers Digestifs, INSERM U866, Facult{\'e} de M{\'e}decine, BP 87 900, France; email: anne-marie.bouvier@u-bourgogne.fr",
year = "2017",
doi = "10.1097/CEJ.0000000000000303",
language = "English",
volume = "26",
pages = "S63--S69",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "supp 1",

}

TY - JOUR

T1 - Trends in net survival from pancreatic cancer in six European Latin countries: Results from the SUDCAN population-based study

AU - Bouvier, A.-M.

AU - Bossard, N.

AU - Colonna, M.

AU - Garcia-Velasco, A.

AU - Carulla, M.

AU - Manfredi, S.

AU - Serraino, Diego

AU - Zucchetto, Antonella

N1 - Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Bouvier, A.-M.; Registre Bourguignon des Cancers Digestifs, INSERM U866, Faculté de Médecine, BP 87 900, France; email: anne-marie.bouvier@u-bourgogne.fr

PY - 2017

Y1 - 2017

N2 - Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10%). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

AB - Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10%). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

KW - Cancer registries

KW - Europe

KW - Excess mortality rate

KW - Net survival

KW - Pancreatic cancer

KW - Trend analysis

KW - adolescent

KW - adult

KW - aged

KW - Article

KW - Belgium

KW - cancer epidemiology

KW - cancer prognosis

KW - cancer registry

KW - female

KW - France

KW - human

KW - Italy

KW - major clinical study

KW - male

KW - mortality rate

KW - pancreas cancer

KW - Portugal

KW - priority journal

KW - Spain

KW - survival

KW - Switzerland

KW - trend study

U2 - 10.1097/CEJ.0000000000000303

DO - 10.1097/CEJ.0000000000000303

M3 - Article

VL - 26

SP - S63-S69

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - supp 1

ER -